Please provide your email address to receive an email when new articles are posted on . CD5 knockout CAR-T exhibited efficacy in several preclinical models. A phase 1 trial will evaluate the approach ...
The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...
PHILADELPHIA – The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a ...
100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- March Biosciences ...
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord ...
Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseases HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio) ...
HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today ...
—Cell Therapy Startup Spun Out of Baylor College of Medicine by Two CPRIT Scholars Awarded Non-Dilutive Funding for Novel Therapy for High-Need Cancer Patients— "We are committed to advancing MB-105 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results